Education and debate: Making regulation responsive to commercial interests: streamlining drug industry watchdogs.
作者信息
Abraham John, Bardelay Danielle, Kopp Christophe, Kleinke J D, Bennion Emma
机构信息
School of Social Sciences, University of Sussex, Brighton BN1 9SN, UK.
出版信息
BMJ. 2002 Nov 16;325(7373):1164-9. doi: 10.1136/bmj.325.7373.1164.
Abstract
摘要
相似文献
1
Education and debate: Making regulation responsive to commercial interests: streamlining drug industry watchdogs.教育与辩论：使监管适应商业利益：精简制药行业监管机构
BMJ. 2002 Nov 16;325(7373):1164-9. doi: 10.1136/bmj.325.7373.1164.
2
Regulators need to regulate. For health and safety issues, the nation needs watchdogs to be on guard.监管机构需要进行监管。对于健康和安全问题，国家需要监管机构保持警惕。
Mod Healthc. 2010 Mar 1;40(9):16.
3
An insider's perspective: defense of the pharmaceutical industry's marketing practices.业内人士视角：制药行业营销行为之辩
Albany Law Rev. 2012;76(1):299-334.
4
Pharmaceutical regulation in the European Community: barriers to single market integration.欧洲共同体的药品监管：单一市场一体化的障碍。
J Health Polit Policy Law. 1992 Winter;17(4):847-68. doi: 10.1215/03616878-17-4-847.
5
Pharmaceuticals and medical devices: business practices. Issue brief.药品和医疗器械：商业行为。问题简报。
Issue Brief Health Policy Track Serv. 2012 Dec 31:1-36.
6
Higher First Amendment hurdles for public health regulation.公共卫生监管面临更高的第一修正案障碍。
N Engl J Med. 2011 Aug 18;365(7):e13. doi: 10.1056/NEJMp1107614. Epub 2011 Aug 3.
7
Drug safety reform at the FDA--pendulum swing or systematic improvement?美国食品药品监督管理局的药物安全改革——是钟摆摆动还是系统性改进？
N Engl J Med. 2007 Apr 26;356(17):1700-2. doi: 10.1056/NEJMp078057. Epub 2007 Apr 13.
8
Pharmaceuticals and medical devices: FDA oversight.药品和医疗器械：美国食品药品监督管理局的监管
Issue Brief Health Policy Track Serv. 2013 Dec 30:1-123.
9
[The regulatory framework for complementary and alternative medicines in Europe].[欧洲补充和替代医学的监管框架]
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2008 Jul;51(7):771-8. doi: 10.1007/s00103-008-0584-8.
10
Off-label or off-limits?未标明的用途还是禁区？
Nat Biotechnol. 2008 Aug;26(8):867-75. doi: 10.1038/nbt0808-867.
引用本文的文献
1
User experiences on implementation of patient reported outcome measures (PROMs)in a Haematological outpatient clinic.患者在血液科门诊实施患者报告结局量表（PROMs）方面的体验。
J Patient Rep Outcomes. 2020 Oct 28;4(1):87. doi: 10.1186/s41687-020-00256-z.
2
Policy Analysis Of Iranian Pharmaceutical Sector; A Qualitative Study.伊朗制药行业的政策分析；一项定性研究。
Risk Manag Healthc Policy. 2019 Nov 7;12:199-208. doi: 10.2147/RMHP.S209318. eCollection 2019.
3
Ocular medicines in children: the regulatory situation related to clinical research.儿童眼部用药：与临床研究相关的监管情况。
BMC Pediatr. 2012 Jan 20;12:8. doi: 10.1186/1471-2431-12-8.
4
Regulation and the social licence for medical research.医学研究的监管与社会许可
Med Health Care Philos. 2008 Dec;11(4):381-91. doi: 10.1007/s11019-008-9152-0. Epub 2008 Jul 17.
本文引用的文献
1
Efficacy, safety, and cost of new anticancer drugs.新型抗癌药物的疗效、安全性及成本
BMJ. 2002 Aug 3;325(7358):269-71. doi: 10.1136/bmj.325.7358.269.
2
Adjusting Europe's drug regulation to public health needs.使欧洲的药品监管适应公共卫生需求。
Lancet. 2001 Jul 7;358(9275):64-7. doi: 10.1016/s0140-6736(00)05258-2.
3
Patient care (empowerment): the view from a national society.
BMJ. 2000 Jun 17;320(7250):1660-2. doi: 10.1136/bmj.320.7250.1660.
4
Whose illness is it anyway? Why patient perceptions matter.
Int J Clin Pract. 1998 Nov-Dec;52(8):551-6.
5
Linking health technology assessment to practice. Interview by Abi Berger.将卫生技术评估与实践相联系。阿比·伯杰访谈录
BMJ. 1999 Nov 13;319(7220):1292. doi: 10.1136/bmj.319.7220.1292.
6
Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I.托卡朋可改善帕金森病运动波动患者的运动功能并减少左旋多巴用量：一项多中心、双盲、随机、安慰剂对照试验。托卡朋波动研究组I。
Neurology. 1997 Jan;48(1):81-7. doi: 10.1212/wnl.48.1.81.
7
Approval of new drugs in the United States. Comparison with the United Kingdom, Germany, and Japan.美国新药审批情况。与英国、德国和日本的比较。
JAMA. 1996 Dec 11;276(22):1826-31.
8
The drug lag issue: the debate seen from an international perspective.药物滞后问题：从国际视角看这场辩论。
Int J Health Serv. 1992;22(1):53-72. doi: 10.2190/9Y32-X86Y-M3F0-JQFC.
Zotero 插件